[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoedema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoedema":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100627052","measuring-fluid-buildup-in-cancer-patients-100627052",false,"NCT07443618","Measuring Fluid Buildup in Cancer Patients","Monitoring of Oedema in Cancer Patients - A Pilot Study","Inclusion Criteria (Outpatient breast cancer patients with lymphoedema after radiotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving radiotherapy due to breast cancer within the last 6 months\n* Is being followed in the Oncology Outpatient Clinic at Aalborg University Hospital\n* Age ≥ 18 years\n* Visible lymphoedema in at least one upper extremity\n\nInclusion Criteria (Hospitalized cancer patients with peripheral oedema in one or both lower extremities after chemotherapy):\n\n* Habile\n* Must be able to speak and read Danish\n* Has received\u002Fis receiving chemotherapy due to cancer within the last 2 months\n* Hospitalised in the Oncology Ward at Aalborg University Hospital\n* Estimated length of hospital stay of at least 6 days\n* Age ≥ 18 years\n* Visible peripheral oedema in at least one lower extremity\n\nExclusion Criteria (both groups):\n\n* Pregnant or breastfeeding women\n* Amputated limb(s)\n* Pacemaker or implanted cardioverter-defibrillator due to risk of interference from the electrical signal\n* Metallic prostheses due to risk of interference with the device signal\n* Inability to lie still for the duration of the measurement interval (minimum 2 minutes at a time)\n* Inability to stand on a scale, i.e. permanently bedridden.\n* Inability to cooperate with urine collection\n* Receiving dialysis\n* Terminal illness","ALL","18 Years",{"count":19,"type":20},46,"ESTIMATED","OBSERVATIONAL","The goal of this study is to improve the monitoring of fluid retention in cancer patients. The main question it aims to answer is: Can segmental bioelectrical impedance analysis be used to monitor local fluid retention (edema) in cancer patients? We will include:\n\n* Breast cancer patients with fluid and or lymph retention in one or both arms after radiotherapy (outpatients)\n* Cancer patients with fluid retention in one or both legs after chemotherapy (hospitalized)\n\nParticipants will:\n\n* Have measurements taken using bioelectrical impedance\n* Provide blood samples and 24-hour urine collection\n* Weight monitorering\n* Complete diet and fluid registration (inclusive enteral and parenteral)\n* Have clinical palpatory and measurement assessment of oedema.",[24,25,26,27,28,29,30],"Cancer","Oedema","Bioelectrical Impedance","Lymphoedema","Chemotherapy","Radiotherapy","Fluid Balance",[32,33,34],"Localized oedema in cancer","Bioelectrical impedance","Post radiation lymphoedema","RECRUITING","2026-04-28",{"date":38,"type":39},"2026-04-29","ACTUAL",{"date":41,"type":39},"2026-02-01",{"date":43,"type":20},"2026-07-31",{"name":45,"class":46},"Jens Rikardt Andersen","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100598599","effect-of-lymphovenous-anastomosis-on-lower-limb-lymphedema-pragmatic-randomized-controlled-trial-100598599","NCT07073586","Effect of Lymphovenous Anastomosis on Lower Limb Lymphedema: Pragmatic Randomized Controlled Trial","Protocol: Effect of Lymphovenous Anastomosis in the Treatment of Lower Limb Lymphedema - Pragmatic Assessor-Blinded Open-Label Randomized Controlled Trial (PrCT)","Inclusion Criteria:\n\n* LLL International Society of Lymphology (ISL) stage 1-2a (both primary and secondary lymphedema and both unilateral and bilateral)\n* Cancer-free with no recurrence for at least one year\n* Age 18 or above\n* Circumference of the affected leg is at least 1 cm larger than the non-lymphedema leg at the most affected site of lymphedema.\n* Proficiency in Danish language, and ability to provide informed consent.\n* Dermal Backflow Stage 0-4\n\nExclusion Criteria:\n\n* LLL International Society of Lymphology (ISL) stage 2b-3\n* Medical conditions contraindicating surgical intervention or anesthesia, such as severe heart or lung disease\n* Allergy to ICG\n* Ongoing infections or skin diseases in the affected limb\n* Previous surgery or other treatment modalities that could interfere with the study results (previous LVA, liposuction or similar).\n* Dermal Backflow Stage 5\n* Active cancer\n* Heart or kidney conditions that can cause leg swelling\n* A BMI above 28 kg\u002Fm²\n* Current smoker\n* Any foreign objects in the lower extremities (e.g., metal implants, prostheses)\n* Venous insufficiency Unilateral weakness in the lower extremity (e.g., after a stroke)\n* Known iodine allergy (contraindication for ICG injection)\n* Leg length discrepancy (anisomelia) \\> 1.5 cm",{"count":56,"type":20},66,"INTERVENTIONAL",[59],"NA","This multicentre pragmatic randomised controlled trial evaluates lymphovenous anastomosis (LVA) for lower-limb lymphedema (LLL) in Denmark. Adults with unilateral or bilateral International Society of Lymphology (ISL) stage 1-2a LLL who have completed protocol-defined Complete Decongestive Therapy (CDT) are randomised 1:1 to\n\nIntervention arm - LVA surgery plus ongoing compression care\n\nControl arm - Compression care only\n\nRecruitment takes place at the Departments of Plastic Surgery, Herlev-Gentofte Hospital and Odense University Hospital. Outcomes are assessed by independent blinded staff at baseline, 6, 12 and 24 months. A biopsy substudy in ten LVA patients explores inflammatory and fibrotic changes. Primary endpoint is change in L-Dex ratio at 12 months. Secondary endpoints include limb volume, infection rate, lymphoscintigraphy findings, patient-reported outcomes, compression-garment use and anastomosis patency.\n\nThe trial follows Good Clinical Practice and General Data Protection Regulation (GDPR). Patients are covered by the Danish public patient-compensation scheme. Results will be published regardless of outcome, and control participants may opt for LVA after the 12-month visit.",[62,27,63,64],"Lymphedema","Lymphoedema of Leg","Lymphedema of Leg",[66,67,68,69,70,71,72],"Lymphovenous Anastomosis","LVA","Lower Limb Lymphedema","Leg Lymphedema","Randomized Controlled Trial","CDT","Compression Therapy","2025-07-29",{"date":75,"type":39},"2025-07-31",{"date":77,"type":39},"2025-05-09",{"date":79,"type":20},"2029-08",{"name":81,"class":46},"Herlev and Gentofte Hospital",2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":47},"100593813","subclinical-monitoring-of-lymphatic-function-in-oncology-patients-for-lymphoedema-prevention-oncolymph-100593813","NCT07011316","Subclinical Monitoring of Lymphatic Function in Oncology Patients for Lymphoedema Prevention (ONCOLYMPH)","Subclinical Assessment and Monitoring of Lymphatic System Function in Oncology Patients as Part of Physiotherapeutic Prevention of Limb Lymphoedema","ONCOLYMPH","Inclusion Criteria:\n\n* admission to the Greater Poland Cancer Centre for treatment in one of the departments participating in the study,\n* age ≥ 18 years,\n* ability to balance independently in a standing position for 30 seconds,\n* obtaining the patient's written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* age ≤ 18 years,\n* cardiac arrhythmia,\n* pacemakers or other implanted electronic devices,\n* history of external defibrillation,\n* pregnancy,\n* critical limb ischaemia,\n* advanced heart failure (NYHA III and IV0),\n* symptoms of deep vein thrombosis,\n* uncompensated heart, kidney or thyroid failure,\n* peripheral nerve damage,\n* presence of psychiatric disorders that preclude informed consent or limit appropriate co-operation of the patient,\n* lack of informed consent from the patient to participate in the study.",{"count":92,"type":20},600,"Lymphoedema, a chronic condition caused by the accumulation of protein-rich fluid in the intercellular spaces due to impaired lymphatic function, is a common complication in cancer patients. It can lead to visible swelling, discomfort, and mobility issues, but most frequently affects the limbs. This condition not only impacts patients physically but also has significant psychological consequences, including reduced quality of life, social stigma, and challenges with returning to daily activities.\n\nOncology patients are particularly at risk for developing lymphoedema due to factors such as lymphadenectomy, radiotherapy, and extensive surgical procedures. Up to 30% of breast cancer survivors develop lymphoedema, and it is also a common complication in patients treated for other cancers, such as those involving the cervix, vulva, prostate, and bladder. Despite the importance of early detection, diagnostic tools for assessing lymphatic dysfunction are often specialised and not suitable for routine screening in clinical practice.\n\nThe primary goal of this study is to explore the early signs of lymphatic dysfunction in cancer patients before evident clinical symptoms, with the aim of identifying individuals at risk of developing lymphoedema. This will provide valuable information that could guide early interventions and preventive measures to reduce the severity or even prevent the onset of lymphoedema. By focusing on early, subclinical dysfunction, the study seeks to contribute to improving both the clinical management of lymphatic complications and the overall quality of life for oncology patients. Regular monitoring and timely physiotherapy interventions could play a key role in enhancing recovery outcomes and reducing the long-term impact of lymphoedema.",[27],[27,24,96,97],"Prevention","bioimpedance spectroscopy","2025-05-30",{"date":100,"type":39},"2025-06-08",{"date":102,"type":39},"2025-01-01",{"date":104,"type":20},"2029-12-31",{"name":106,"class":46},"The Greater Poland Cancer Centre"]